rs72547517 — CYP1A2 *8

CYP1A2*8 — Near-Complete Loss of Liver Enzyme Activity

CYP1A2¹¹ CYP1A2
Cytochrome P450 family 1 subfamily A member 2 — the liver enzyme that processes about 95% of caffeine and several widely prescribed medications is one of the most clinically relevant drug-metabolizing enzymes in the body. The CYP1A2*8 allele (rs72547517) is a missense variant that substitutes histidine for arginine at position 456 of the enzyme (p.Arg456His), crippling the enzyme's ability to fold around its heme cofactor and carry out oxidative metabolism. This allele is extremely rare in most global populations but occurs at measurable frequency in Japanese and broader East Asian populations.

The Mechanism

Arginine-456 sits in a structurally critical region of the CYP1A2 protein. The substitution to histidine disrupts the tertiary folding required for heme incorporation — the spectral peak at 450 nm that defines an active cytochrome P450 enzyme is barely detectable in cells expressing the *8 variant. Without the iron-containing heme cofactor properly seated, the enzyme cannot perform the oxygen-insertion reactions that metabolize drugs and other substrates.

Saito et al. (2005)²² Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 expressed the *8 variant in Chinese hamster V79 cells and a baculovirus system, measuring its activity against [7-ethoxyresorufin | A standard CYP1A2 probe substrate used to assess oxidative activity in vitro] and phenacetin. The variant retained approximately 30% of wild-type protein expression but showed less than 3% of wild-type maximum velocity (Vmax), and less than 1% of the catalytic efficiency (Vmax/Km) — effectively a non-functional enzyme despite being present in the cell.

The Evidence

The functional characterisation by Saito et al. (2005)³³ Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 established CYP1A2*8 as a severe loss-of-function allele in vitro, with catalytic efficiency less than 1% of wild-type. This places it among the most functionally damaging CYP1A2 variants identified.

Population data from the 38KJPN Japanese genome project records the A allele at approximately 0.65% frequency (501/77,444 alleles), compared with near-zero frequency in European and African cohorts. The global TopMed frequency is ~0.005% (1 in 20,000 alleles). This extreme population stratification means the clinical relevance of *8 is almost entirely concentrated in East Asian individuals.

Because individuals carrying two *8 alleles (AA homozygotes) are expected to be vanishingly rare even in Japanese populations, the most clinically actionable scenario is a heterozygous carrier (AG) who also carries a second non-functional or reduced-function CYP1A2 allele — creating a compound heterozygous [poor metabolizer | Poor metabolizer (PM): both copies of the gene carry loss-of-function alleles, leaving the individual with minimal enzyme activity] state.

Practical Actions

CYP1A2 poor metabolizers have substantially reduced clearance of caffeine, theophylline, and certain psychiatric medications. The most clinically significant implications are:

Theophylline: a narrow therapeutic index bronchodilator where twofold differences in clearance can shift a patient from sub-therapeutic to toxic plasma levels. Poor metabolizers require lower doses and close plasma-level monitoring.

Clozapine and olanzapine: both antipsychotics are primarily cleared by CYP1A2. Poor metabolizers can accumulate several-fold higher plasma concentrations at standard doses, increasing the risk of sedation, QTc prolongation, and other dose-dependent adverse effects.

Caffeine: while not a medication safety issue for most people, the near-complete loss of CYP1A2 activity means caffeine is cleared extremely slowly, amplifying both its stimulant effects and its potential to disrupt sleep.

Carcinogen bioactivation: CYP1A2 activates [heterocyclic amines | Compounds formed in grilled and charred meats (e.g. PhIP, IQ) that require CYP1A2 activation to become DNA-damaging carcinogens] from grilled and charred meat into DNA-damaging intermediates. Reduced CYP1A2 activity in *8 carriers may alter their net carcinogen exposure from dietary sources, though the direction of effect depends on competing detoxification pathways.

Interactions

CYP1A2 activity is powerfully modified by environmental factors — tobacco smoke and cruciferous vegetables induce CYP1A2, while fluvoxamine, ciprofloxacin, and omeprazole inhibit it. These interactions act on top of the genetic baseline. A *8 carrier who also smokes will still have minimal enzyme activity because the structural basis for inducibility is eliminated by the missense change.

The common CYP1A2 regulatory variant rs762551 (*1F) acts through a completely different mechanism — inducibility — and does not compensate for the structural loss of function caused by *8. Carriers of both rs762551 C and rs72547517 A would have reduced inducibility compounded by structural loss of function on the *8 chromosome.